期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 1, 页码 14-28出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1323272
关键词
Multiple myeloma; bonedisease; bisphosphonates; novel therapies; clinical trials
资金
- Belgian Foundation against Cancer
- Fonds National de la Recherche Scientifique (FNRS), Fonds Leon Fredericq and Fonds Speciaux de la Recherche - University of Liege
- AXA Research Fund and JC is a post- doctorate clinical specialist - Belgian Foundation against Cancer
Multiple myeloma (MM) bone disease is a major cause of morbidity and mortality in MM patients and persists even in patients in remission. This bone disease is caused by an uncoupling of bone remodeling, with increased osteoclast and decreased osteoblast activity and formation, culminating in lytic bone destruction. Bisphosphonates are the current standard of care but new therapies are needed. As the molecular mechanisms controlling MM bone disease are increasingly well understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds now show promising results. In this review, we will provide a comprehensive overview of the biology of MM bone disease, summarize its current clinical management and discuss preclinical and clinical data on next generation therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据